Enlivex Dividend Paid And Capex Coverage Ratio from 2010 to 2024
| ENLV Stock | USD 1.14 0.07 6.54% |
Dividend Paid And Capex Coverage Ratio | First Reported 2010-12-31 | Previous Quarter (99.67) | Current Value (104.66) | Quarterly Volatility 253.93759171 |
Check Enlivex Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Enlivex Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 13.3 K, Total Revenue of 0.0 or Research Development of 20.2 M, as well as many indicators such as Price To Sales Ratio of 39.01, Dividend Yield of 0.0 or PTB Ratio of 1.58. Enlivex financial statements analysis is a perfect complement when working with Enlivex Therapeutics Valuation or Volatility modules.
Enlivex | Dividend Paid And Capex Coverage Ratio |
Latest Enlivex Therapeutics' Dividend Paid And Capex Coverage Ratio Growth Pattern
Below is the plot of the Dividend Paid And Capex Coverage Ratio of Enlivex Therapeutics over the last few years. It is Enlivex Therapeutics' Dividend Paid And Capex Coverage Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Enlivex Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Dividend Paid And Capex Coverage Ratio | 10 Years Trend |
|
Dividend Paid And Capex Coverage Ratio |
| Timeline |
Enlivex Dividend Paid And Capex Coverage Ratio Regression Statistics
| Arithmetic Mean | (214.36) | |
| Coefficient Of Variation | (118.46) | |
| Mean Deviation | 210.69 | |
| Median | (99.67) | |
| Standard Deviation | 253.94 | |
| Sample Variance | 64,484 | |
| Range | 857 | |
| R-Value | 0.61 | |
| Mean Square Error | 43,933 | |
| R-Squared | 0.37 | |
| Significance | 0.02 | |
| Slope | 34.42 | |
| Total Sum of Squares | 902,780 |
Enlivex Dividend Paid And Capex Coverage Ratio History
About Enlivex Therapeutics Financial Statements
Enlivex Therapeutics investors use historical fundamental indicators, such as Enlivex Therapeutics' Dividend Paid And Capex Coverage Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Enlivex Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Dividend Paid And Capex Coverage Ratio | (99.67) | (104.66) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Enlivex Stock Analysis
When running Enlivex Therapeutics' price analysis, check to measure Enlivex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enlivex Therapeutics is operating at the current time. Most of Enlivex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Enlivex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enlivex Therapeutics' price. Additionally, you may evaluate how the addition of Enlivex Therapeutics to your portfolios can decrease your overall portfolio volatility.